Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28500448 | 0.82 | TDP1 (0.45) | TDP1TSHRALDH1A1GAAMAPT | |
| SCHEMBL9280069 | 0.80 | TDP1 (0.55) | TDP1TSHRALDH1A1GAAMAPT | |
| SCHEMBL57069 | 0.80 | TSHR (0.52) | TDP1TSHRALDH1A1GAAMAPT | |
| SCHEMBL1076199 | 0.80 | TDP1 (0.42) | TDP1TSHRALDH1A1GAAMAPT | |
| SCHEMBL28570919 | 0.80 | TDP1 (0.50) | TDP1TSHRALDH1A1GAAMAPT | |
| SCHEMBL8627208 | 0.79 | TSHR (0.46) | TDP1TSHRALDH1A1GAAMAPT | |
| SCHEMBL10534450 | 0.79 | TDP1 (0.46) | TDP1TSHRALDH1A1GAAMAPT | |
| SCHEMBL28559374 | 0.78 | TDP1 (0.53) | TDP1TSHRALDH1A1GAAMAPT | |
| SCHEMBL8865453 | 0.78 | TSHR (0.50) | TDP1TSHRALDH1A1GAAMAPT | |
| Lithium SCHEMBL31366079 | 0.78 | TSHR (0.50) | TDP1TSHRALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011083495-A2 | PROCESS FOR THE PREPARATION OF DIHYDROXY PROTECTED DERIVATIVES AND NOVEL INTERMEDIATE COMPOUNDS | MSN LABORATORIES LIMITED (IN) | 2011-07-14 | — | — | WO | claimed |
| JP-4649813-B2 | — | — | 2011-03-16 | — | — | JP | claimed |
| US-20040181065-A1 | Process for preparing 2-amino-4-(4-fluorphenyl) -6-alkylpyrimidine-5-carboxylate | VEITH ULRICH (CH) | 2004-09-16 | — | — | US | claimed |
| US-20030199695-A1 | Preparation of 4-(4-flourophenyl)-6-alkyl-2-N-alkansulfonyl-N-alkylamino)pyrimidine-5-carboxylic acid ester. | VEITH ULRICH (CH) | 2003-10-23 | — | — | US | claimed |
| JP-2003504359-A | — | — | 2003-02-04 | — | — | JP | claimed |
| EP-1194414-A1 | PROCESS FOR PREPARING 2-AMINO-4-(4-FLUORPHENYL)-6-ALKYLPYRIMIDINE-5-CARBOXYLATE | Lonza AG (CH) | 2002-04-10 | — | — | EP | claimed |
| WO-2001004100-A1 | PROCESS FOR PREPARING 2-AMINO-4-(4-FLUORPHENYL)-6-ALKYLPYRIMIDINE-5-CARBOXYLATE | LONZA AG (CH) | 2001-01-18 | — | — | WO | claimed |
| CN-103864697-A | Preparation method of rosuvastatin intermediate main chain alcohol | RUNZE PHARMACEUTICAL SUZHOU CO LTD | 2014-06-18 | — | — | CN | disclosed |
| WO-2011083495-A2 | PROCESS FOR THE PREPARATION OF DIHYDROXY PROTECTED DERIVATIVES AND NOVEL INTERMEDIATE COMPOUNDS | MSN LABORATORIES LIMITED (IN) | 2011-07-14 | — | — | WO | disclosed |
| WO-2009084827-A2 | SYNTHETIC INTERMEDIATES, PROCESS FOR PREPARING PYRROLYLHEPTANOIC ACID DERIVATIVES THEREFROM | DONG-A PHARM.CO., LTD. (KR) | 2009-07-09 | — | — | WO | disclosed |
| US-6984757-B2 | Process for preparing 2-amino-4-(4-fluorphenyl)-6-alkylpyrimidine-5-carboxylate | LONZA AG (CH) | 2006-01-10 | — | — | US | disclosed |
| US-20040181065-A1 | Process for preparing 2-amino-4-(4-fluorphenyl) -6-alkylpyrimidine-5-carboxylate | VEITH ULRICH (CH) | 2004-09-16 | — | — | US | disclosed |
| US-6710178-B2 | CYCLIZATION REACTION OF A 2-(-1-AMINO-1-(4- FLOUROPHENYL )METHYLENE)-4-ALKYL-3-OXO-ALKANOIC ACID ESTER AND AN N-CYANO-N-ALKYLALKANESULFONAMIDE | LONZA AG (CH) | 2004-03-23 | — | — | US | disclosed |
| US-20030199695-A1 | Preparation of 4-(4-flourophenyl)-6-alkyl-2-N-alkansulfonyl-N-alkylamino)pyrimidine-5-carboxylic acid ester. | VEITH ULRICH (CH) | 2003-10-23 | — | — | US | disclosed |
| EP-1339818-A2 | INTERFACE-ACTIVE COMBINATION, WHICH IS EFFECTIVE IN CLEANING, WHICH IS COMPRISED OF RENEWABLE RAW MATERIALS, AND WHICH HAS A HIGH GREASE SOLUBILIZING POWER | Novaprot GmbH (DE) | 2003-09-03 | — | — | EP | disclosed |
| US-6579984-B1 | Economical, industrially feasible | LONZA AG (CH) | 2003-06-17 | — | — | US | disclosed |
| WO-2002046342-A2 | INTERFACE-ACTIVE COMBINATION, WHICH IS EFFECTIVE IN CLEANING, WHICH IS COMPRISED OF RENEWABLE RAW MATERIALS, AND WHICH HAS A HIGH GREASE SOLUBILIZING POWER | NOVAPROT GMBH (DE) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199695-A1 | Preparation of 4-(4-flourophenyl)-6-alkyl-2-N-alkansulfonyl-N-alkylamino)pyrimidine-5-carboxylic acid ester. | PFAS, F7, AFF1 | TDP1 3614/4885TSHR 1577/4885ALDH1A1 299/4885 |
| US-20040181065-A1 | Process for preparing 2-amino-4-(4-fluorphenyl) -6-alkylpyrimidine-5-carboxylate | ALKBH1, F7, CYP2B6 | TDP1 3145/4885TSHR 1950/4885ALDH1A1 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.